Julie Jordan - 26 Mar 2025 Form 4 Insider Report for Neurogene Inc. (NGNE)

Role: Chief Medical Officer
Signature: /s/ Christine Mikail, as attorney-in-fact for Julie Jordan
Issuer symbol: NGNE
Transactions as of: 26 Mar 2025
Net transactions value: $0
Form type: 4
Filing time: 28 Mar 2025, 21:28:27 UTC
Previous filing: 18 Jan 2024
Next filing: 24 Feb 2026
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NGNE	Common Stock	Award	$0	+8,400		$0.000000	8,400	26 Mar 2025	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NGNE	Employee Stock Option (Right to buy)	Award	$0	+50,300		$0.000000	50,300	26 Mar 2025	Common Stock	50,300	$16.14	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Consist of 8,400 restricted stock units, which will vest in three equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued provision of services to the Issuer on each vesting date.
F2	This option represents the right to purchase 50,300 shares of the Issuer's common stock, one quarter of which will vest on the first anniversary of the grant date with the remaining three quarters vesting in equal monthly installments through the fourth anniversary of the grant date, subject to the Reporting Person's continued provision of service to the Issuer on each vesting date.